subject who complete exit or discontinue for reason other than safety from the 18-week treatment phase of protocol 093-045 or 093-046 and be willing to continue participation in this study be eligible subject must have complete at least the first 3 week of the 18-week double-blind treatment period of protocol 093-045 or 093-046 to be eligible 